<生产厂家价格>

N,N’-二环己基脲

N,N’-二环己基脲用途

1,3-二环己基脲(DCU)是一种口服活性强的sEH(可溶性环氧化物水解酶)抑制剂。口服1,3-二环己基脲纳米混悬剂可增强暴露并降低高血压大鼠的血压【1】。

N,N’-二环己基脲名称

[ CAS 号 ]:
2387-23-7

[ 中文名 ]:
N,N-二环己脲

[ 英文名 ]:
1,3-Dicyclohexylurea

[中文别名 ]:

[英文别名 ]:

F0902-7614
MFCD00003829
EINECS 219-213-7
N,N'-Dicyclohexylurea
1,3-Dicyclohexylurea
N,N-Dicyclohexylurea
Urea, N,N'-dicyclohexyl-
Urea,3-dicyclohexyl
dicyclohexyl urea
N,N‘-Dicyclohexylurea

N,N’-二环己基脲生物活性

[ 描述 ]:

1,3-二环己基脲(DCU)是一种口服活性强的sEH(可溶性环氧化物水解酶)抑制剂。口服1,3-二环己基脲纳米混悬剂可增强暴露并降低高血压大鼠的血压【1】。

[ 相关类别 ]:

研究领域 >> 心血管疾病

[体内研究]

1,3-二环己基脲(Sprague-Dawley大鼠,30 mg/kg,口服,一次)在研磨以减小粒径时显示出抗高血压功效,从而改善溶解性和口服生物利用度[1]。

[参考文献]

[1]. Ghosh S, et al. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin Pharmacol Toxicol. 2008 May;102(5):453-8.

N,N’-二环己基脲物理化学性质

[ 密度 ]:
1.2±0.1 g/cm3

[ 沸点 ]:
364.3±25.0 °C at 760 mmHg

[ 熔点 ]:
232-233 °C(lit.)

[ 分子式 ]:
C₁₃H₂₄N₂O

[ 分子量 ]:
224.34

[ 闪点 ]:
174.1±23.2 °C

[ 精确质量 ]:
224.188858

[ PSA ]:
41.13000

[ LogP ]:
3.85

[ 外观性状 ]:
固体;White to Light yellow powder to crystal

[ 蒸汽压 ]:
0.0±1.8 mmHg at 25°C

[ 折射率 ]:
1.586

[ 储存条件 ]:
室温

N,N’-二环己基脲MSDS

N,N’-二环己基脲安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302

[ 警示性声明 ]:
P301 + P312 + P330

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xn: Harmful;N: Dangerous for the environment;

[ 风险声明 (欧洲) ]:
22-51/53

[ 安全声明 (欧洲) ]:
S61

[ 危险品运输编码 ]:
UN 3077 9 / PGIII

[ WGK德国 ]:
3

[ 海关编码 ]:
2924299090

N,N’-二环己基脲合成路线

N,N’-二环己基脲上下游产品

N,N’-二环己基脲上游产品

N,N’-二环己基脲下游产品

N,N’-二环己基脲制备

将环己胺和尿素（配料比1：0.41，mol）在异戊醇中回流反应20h，冷却，过滤，用乙醚洗涤滤饼，干燥，得1,3-二环己基脲，产率89%。

N,N’-二环己基脲海关

[ 海关编码 ]: 2924299090

[ 中文概述 ]:
2924299090. 其他环酰胺（包括环氨基甲酸酯）（包括其衍生物以及他们的盐）. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 包装

[ Summary ]:
2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

N,N’-二环己基脲文献

A dual wavelength-activatable gold nanorod complex for synergistic cancer treatment.

Nanoscale 7 , 12096-103, (2015)

A multifunctional gold nanorod (AuNR) complex is described with potential utility for theranostic anticancer treatment. The AuNR was functionalized with cyclodextrin for encapsulation of doxorubicin, ...

Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate.

Int. J. Pharm. 470(1-2) , 51-62, (2014)

Gemcitabine, a nucleoside analogue, is used in the treatment of various solid tumors, however, its efficacy is limited by rapid metabolism by cytidine deaminase and fast kidney excretion. In this stud...

Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles.

J. Microencapsul. 31(5) , 479-87, (2014)

Liver cancer is widespread liver malignancy in the world, for an estimated one million deaths annually.In present work, lactobionic acid conjugated PLGA nanoparticles (LDNPs) bearing 5-Fluorouracil (5...

更多文献